Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival, using best separation (to the left) and median separation (to the right). Patients were divided based on level of expression into one of the two groups "low" or "high". Below each Kaplan-Meier plot, corresponding expression cutoff, 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For melanoma and glioma, 3-year survival is shown. The survival analysis is described in Assays & Annotation.

The tabs at the top of the survival analysis section can be used to switch between the different cancer subtypes.

Survival analysis data not available.

LYMPHOMA - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

Antibody stainingi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival, using best separation (to the left) and median separation (to the right). Patients were divided based on level of expression into one of the two groups "low" or "high". Below each Kaplan-Meier plot, corresponding expression cutoff, 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For melanoma and glioma, 3-year survival is shown. The survival analysis is described in Assays & Annotation.

The tabs at the top of the survival analysis section can be used to switch between the different cancer subtypes.